Kyowa Hakko: Pipeline, Products, Performance, Potential

Table of Contents

LATEST RESULTS

EXECUTIVE SUMMARY

• INTRODUCTION
• FINANCIAL PERFORMANCE 2005
  • Sales and market position
  • Income
    • Sales, Costs and Operating Income
  • Expenditure
    • Capital expenditure
    • Capital Expenditure By Business Area
    • Capital Expenditure By Business Area, 2005
    • R&D expenditure
    • R&D Expenditure and Capital Expenditure
  • Divisional performance
    • Sales By Business Area
    • Sales By Business Area
    • Operating Income (Loss) By Business Area
    • Total Assets By Business Area
  • Geographic performance
    • Sales By Destination
    • Sales By Destination
    • Overseas Sales By Region, 2005
• COMPANY STRATEGY
  • Eighth Medium-Term Management Plan
  • Financial targets (consolidated)
  • Mergers, acquisitions and divestitures
  • Key agreements
  • Production
  • Employees
    • Employees and Productivity
• PRODUCT / R&D OVERVIEW
  • Key products
    • Recent Product Launches
    • Recent Product Approvals
  • R&D strategy
    • Key R&D projects
  • R&D pipeline overview
  • Sales forecast
    • Sales of current top ten products (2000A-2010E)
• CONCLUSIONS

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

• Major Products, Therapeutic Areas and Sales
• Sales of Major Pharmaceutical Products, 2005
• R&D Pipeline - Japan
• R&D Pipeline - Overseas

• ANTI-INFECTIVE PRODUCTS
• ANTI-INFECTIVE SUMMARY
• CARDIOVASCULAR PRODUCTS
  • Major launched products
  • Coniel
    • Sales
    • Key markets/indications
    • Competitor products
    • Sales forecast
  • Coniel sales (2000A-2010E)
  • Activacin
  • Others
• CARDIOVASCULAR SUMMARY
  • Growth potential
  • Limiting factors
• ANTI-ALLERGY PRODUCTS
  • Major launched products
  • Allelock
    • Sales
    • Key markets/indications
    • Further development
    • Competitor products
    • Sales forecast
  • Allelock sales (2000A-2010E)
  • Celtect
    • Sales
    • Key markets/indications/formulations
    • Competitor products
    • Sales forecast
  • Celtect sales (2000A-2010E)
• ANTI-ALLERGY SUMMARY
  • Growth potential
  • Limiting factors
• CENTRAL NERVOUS SYSTEM PRODUCTS
  • Durotep
    • Sales
    • Key markets/indications/formulations
    • Competitor products
    • Sales forecast
  • Durotep sales (2000A-2010E)
  • Depakene
    • Sales
    • Key markets/indications/formulations
    • Competitor products
    • Sales forecast
  • Depakene sales (2000A-2010E)
  • Others
• CENTRAL NERVOUS SYSTEM R&D
  • Topiramate (KW-6485)
  • Istradeylline (KW-6002)
    • Clinical trials
  • KW-2246
• CENTRAL NERVOUS SYSTEM SUMMARY
  • Growth potential
  • Limiting factors
• ANTICANCER PRODUCTS
  • Adriacin/Farmorubicin
    • Sales
    • Key markets/indications/formulations
    • Sales forecast
  • Adriacin/Farmorubicin sales (2000A-2010E)
  • 5-FU
    • Sales
    • Sales forecast
  • 5-FU sales (2000A-2010E)
  • Navelbine
    • Clinical trials
  • Others
• ANTICANCER R&D
  • KW-2401 (UCN-01)
  • Lestaurtinib (KT5555)
  • KW-2871
  • FGF8
• ANTICANCER SUMMARY
  • Growth potential
  • Limiting factors
• GASTROINTESTINAL PRODUCTS
  • Major launched products
  • Nauzelin
    • Sales
    • Sales forecast
  • Nauzelin sales (2000A-2010E)
  • Acenalin
  • Navoban
  • Others
• GASTROINTESTINAL SUMMARY
• BLOOD AND FLUID DISORDER PRODUCTS
  • Major launched products
  • Neu-up
    • Sales
    • Key markets/indications/formulations
    • Competitor products
    • Sales forecast
  • Neu-up sales (2000A-2010E)
  • Leukoprol
• BLOOD AND FLUID DISORDER SUMMARY
• OTHERS PRODUCTS
  • Desmopressin
  • Imagenil
• OTHERS R&D
  • Potelligent technology
  • MM-Q01
  • KW-3902
  • KW-7158

APPENDIX 1 - FINANCIAL PERFORMANCE

• FULL YEAR RESULTS 2005
  • Sales, Costs and Operating Income
  • Profitability and Research Ratios
  • Current Assets, Liabilities and Ratio
  • Assets, Cash and Liquidity

APPENDIX 2 - KEY CORPORATE EVENTS

APPENDIX 3 - KEY AGREEMENTS

• Astellas Pharma Inc
  • 1st October 2005
• BioGenex
  • 23rd July 1997
• Biogen Idec Inc
  • 30th June 2004
• BioWa
  • 22nd March 2005
  • 21st October 2005
• Cephalon Inc
  • Signal transduction modulators agreement
  • 15th May 1992
• Compugen Ltd
  • 17th July 2001
• Eli Lilly
  • 10th January 2006
• Eurand SpA
  • 20th January 2003
• Genomatica Inc
  • 5th January 2005
• Medarex Inc
  • 24th May 2005
• MedImmune Inc
  • 7th December 2005
• Mitsubishi Pharma Corporation
  • 18th October 2000
• NovaCardia Inc
  • 9th October 2003
• OncoTherapy Science Inc (OTS)
  • 24th October 2005
• Orexo Pharmaceuticals AB
  • 14th January 2003
• Sigma Company Limited
  • 5th July 1999
• Taisho Pharmaceutical Co Ltd
• Others
• Discontinued Agreements
  • Johnson & Johnson
    • 24th February 2005
  • Geron Corporation
    • 30th June 2004

APPENDIX 4 - INFRASTRUCTURE

• RESEARCH AND DEVELOPMENT FACILITIES
• MANUFACTURING FACILITIES

APPENDIX 5 - MAJOR PHARMACEUTICAL SUBSIDIARIES/JOINT VENTURES

• SUBSIDIARIES
• JOINT-VENTURE COMPANIES

APPENDIX 6 - PRODUCT INDEX